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THE STUDY
This was a post-hoc subgroup analysis of the CLUE trial to compare the safety and efficacy of FDA recommended dosing of IV nicardipine versus labetalol for the management of acute hypertension, with focus on the patients with S/S suggestive of EOD on arrival. Same methodologies were used to analyze and present the data as in the main paper.
Although the authors have made it clear that the original CLUE trial was reported elsewhere and briefly described here, which level of details should be presented in this second manuscript requires more careful consideration.
The primary outcome was indeed a binary indicator whether the patient achieved TR within 30 minutes of the treatment. Either numbers or percentage should not be stated as the outcome measure but the inference made to compare between the groups.
Results presented in the abstract have error (e.g. 95% CI) with no level of significance reported on the primary outcome analysis which is often the key message.
The statistical analysis section needs to be revised and describe more on how the outcomes were compared rather than patients characteristics at baseline. It is also unclear whether unadjusted or adjusted tests were considered as the primary analysis to evaluate the main trial effect. It should be noted that statistical tests for baseline imbalance in randomized trials are merely descriptive, which are due to either chance or error in randomization. It is obviously inappropriate to consider all measured baseline variables for inclusion in an adjusted analysis. Only those known a prior to be strongly correlated with the outcome should be considered. RESULTS & CONCLUSIONS It is not generally recommended to report p-values for baseline characteristics, as any imbalance between groups are due to either chance or error in randomization. How the results in Figure 1 and 2 were obtained was not described in the manuscript. The level of significance in the unadjusted and adjusted tests on the primary outcome were not presented. Interpretation on the odds ratio (OR) was incorrect, which is known to be a different measure from risk ratio (or RR).
Some other notes. This was a post-hoc subgroup analysis of the CLUE trial to compare the safety and efficacy of FDA recommended dosing of IV nicardipine versus labetalol for the management of acute hypertension, with focus on the patients with S/S suggestive of EOD on arrival. Same methodologies were used to analyze and present the data as in the main paper.
1. The primary outcome was indeed a binary indicator whether the patient achieved TR within 30 minutes of the treatment. Either numbers or percentage should not be stated as the outcome measure but the inference made to compare between the groups.
A: While the primary outcome is a binary outcome, we believe it is most informative with its value reported as a percentage. The following sentence was added in the statistical analysis section for clarification as well: "The proportion of patients in each arm achieving the target SBP within 30 minutes was compared with chi-square analysis."
2. Results presented in the abstract have error (e.g. 95% CI) with no level of significance reported on the primary outcome analysis which is often the key message.
A: We have amended the abstract to include respective p-values.
3. The statistical analysis section needs to be revised and describe more on how the outcomes were compared rather than patients characteristics at baseline. It is also unclear whether unadjusted or adjusted tests were considered as the primary analysis to evaluate the main trial effect. It should be noted that statistical tests for baseline imbalance in randomized trials are merely descriptive, which are due to either chance or error in randomization.
A: The following sentences were added to statistical analysis section of the manuscript for clarification:
"The proportion of patients in each arm achieving the target SBP within 30 minutes was compared with chi-square analysis."
"Main effect was also tested in the multivariable model to assess the treatment difference. All possible interactions with treatment were also evaluated during this process."
It is obviously inappropriate to consider all measured baseline variables for inclusion in an adjusted analysis. Only those known a prior to be strongly correlated with the outcome should be considered.
A: We did not include all measured baseline variables in the model, just those which met our predefined cut-point for significance on univariate assessment. The model was refined using stepwise elimination as described in our methods section, resulting in inclusion of variables (with the exception of site which was forced into the model) that were statistically associated with the outcome.
4. It is not generally recommended to report p-values for baseline characteristics, as any imbalance between groups are due to either chance or error in randomization.
A: P-values for baseline characteristics have been removed.
How the results in Figure 1 and 2 were obtained was not described in the manuscript.
A: We have added a statement that Figure 1 was derived by Student's t-test and Figure 2 by MannWhitney U-test to the manuscript.
The level of significance in the unadjusted and adjusted tests on the primary outcome were not presented.
A: As noted in our methods, only those variables with a p-value < 0.05 on adjusted analysis were included in the final model. Interpretation on the odds ratio (OR) was incorrect, which is known to be a different measure from risk ratio (or RR).
A: The sentence immediately before table 3 has been reworded for clarity of interpreting the odds ratio:
"The odds of being in the target range within 30 minutes for patients treated with nicardipine was more than 3 times than that of patients receiving labetalol (OR 3.65 [95% CI: 1.31 to 10.18]; pvalue=0.02, c-statistic = 0.72)."
5. Some other notes. Table 2 (now Table 1 ) didn't indicate that both n and % were reported for categorical variables, and the denominators on the numbers observed for some measures can introduce confusion. Abbreviations should be avoided without proper references. There are also errors in the results section, e.g. 95% CI for the primary outcome were reported differently in wrong format in the abstract and main text.
A: Table 1 (was Table 2 ) has been edited and only %'s are reported (where indicated) and denominators have been removed to avoid confusion. The 95% CIs for the primary outcome have been corrected to be consistent and reflect that nicardipine is the reference group.
6. The main results from this post-hoc subgroup analysis have been briefly reported in the CLUE trial paper on page 4, "Signs and symptoms of end-organ damage preceding treatment occurred in 143 (63.3%), and at similar rates between cohorts (n= 71, 64.5% for nicardipine, and n= 72, 62.1% for labetalol) ... Similar to the overall group, more end-organ damage patients receiving nicardipine were within target range within 30 minutes, than those treated with labetalol, 91.4% vs 76.1% (P= 0.014), respectively."
A: The reviewer is correct that the results have been partially presented in the overall CLUE manuscript but, since EOD is the focus of this subanalysis, their inclusion here is essential.
7. As the authors stated, this investigation used the same methodologies to analyze and present the data as in the main trial, and showed very similar results to the overall group. With known limitations in any post-hoc subgroup analysis, it appears to be little benefit to publish the results as a full manuscript in addition to what has been reported in the main paper. The authors should demonstrate with more convincing evidence on their initial assumption that "hypertensive individuals with suspected EOD may have different treatment responses than those without". Information on the latter, however, has not been reported previously.
A: We believe there is benefit in publishing this manuscript in addition to the main paper. As mentioned in the discussion, this post-hoc analysis represents a unique population, separate from the overall CLUE study. CLUE allowed enrollment of all patients with elevated BP in whom the physician felt IV BP control was required. Patients with numerically high BPs, but who are otherwise asymptomatic were thus included. These patients may represent a cohort with different physiology than those with EOD. Patients with EOD would be expected to have an ongoing adverse responsive to a hypertensive stimulus that is presumably absent in the asymptomatic patient. Thus the population of patients with EOD could represent a cohort for whom obtaining BP control would be more difficult. Emergency physicians must initially treat patients without any confirmatory diagnostics, strictly based on clinical gestalt. It has never been described whether EOD patients represent a particularly resistant cohort requiring different dosing parameters than non-EOD patients. Knowing that EOD patients respond in similar fashion to non-EOD patients will help this cohort receive optimal treatment in the future.
In an attempt to answer the reviewers request for more convincing evidence on our initial assumption that hypertensive individuals with suspected EOD may have different treatment responses than those without, we have re-analyzed all 226 patients (from the original CLUE trial) regardless of pharmaceutical treatment received and compared the proportion of patients with and without end organ damage (EOD) that met target SBP within 30 mins. As shown in the 1. The dosing of nicardipine seems particularly low; median of 3.2 mg with range of 1.1 to 6.7 mg. The package insert recommends starting at a dose of 5mg/hr. In view of the findings of this study, would the authors recommend a lower starting dose. eg 3mg/hr. Furthermore 11.4% of nicardipine patients received rescue medications; why was the dosage just not increased more aggressively on these patients; the maximal dose of 6.7 mg seems quite low.
A: All patients were started on at a dose consistent with the package insert (5 mg/hr) with titration as clinically indicated. The study was not designed to assess the optimal dosing thus any conclusion related to this would be beyond the scope of this trial.
Regarding the use of rescue medications, it is important to remember that these were tracked after the initial treatment period (a statement to this effect has been added to the manuscript). For study purposes, we simply recorded what occurred and did not attempt to define why physicians chose to titrate at the schedule that they did; any description of as to why the dosage was not further increased would be strictly speculative.
2. On page 18 the authors state "Vaughan et al in a recent lancet review"; this paper was published in 2000; most would not consider this "recent".
A: "recent" has been removed in the manuscript. A: 200 ml ready-to-use (RTU) bags containing 20 mg of nicardipine hydrochloride (0.1 mg/ml) were used. Because this was a trial of nicardipine not the proprietary RTU formulation, we did feel it was appropriate to mention the specific preparation in the manuscript.
2. How was randomization completed for each site?
A: As reported in the primary CLUE paper and referenced in our paper: Randomization was stratified by site. At each site patients were randomized in a 1:1 ratio. Allocation to nicardipine or labetalol was balanced in blocks of four for each of the 13 sites. Sealed envelopes were created by C5 (the coordinating research organization), and provided to the sites. Each had a label indicating the protocol name, site number, and patient study ID number. Randomization slips in the envelope contained the same information as the labels, as well as the randomized treatment. Sequence was concealed until interventions were assigned. Patients were enrolled by each site's research coordinator who was blinded to the randomization process. We did not think it was necessary to include this in the present manuscript as it is in main CLUE paper but can add this if the editor feels further information on randomization is warranted.
3. on page 10, line 41 and 43, tables 1 and table 2 are mislabeled on pages 11 and 12. Table 1  should be table 2, and table 2 should be table 1. A: These tables have been relabeled and reordered in the manuscript.
4. page 13, line 10, remove the :
A: This has been removed.
5. Why do you think the labetalol doses were so low?
A: Unclear but it may relate to an expectation of a delayed BP effect by treating clinicians. However, as noted above, any consideration of this would be speculative and thus provide limited added value to the manuscript.
Based upon the results of this study, what further research is necessary?
A: Future investigation is needed to place our findings within the context of hospital costs and resource allotment. Future research evaluating therapeutic responses in patients with confirmed end organ damage as opposed to patients only with signs and symptoms of end organ dysfunction would also be of value. 
